Roche teams up with transcription factor trailblazer Flare in new $1.8B-plus cancer pact

Roche and Flare Therapeutics are igniting a partnership worth more than $1.8 billion in biobucks with hopes of discovering new small molecule cancer treatments via previously undruggable transcription factor targets.